BioRestorative Therapies Inc (BRTX) Stock Analysis
Verdict: AVOID
Imminent cash exhaustion and the expiration of share lock-ups create a toxic setup for a sub-$5M biotech with no near-term revenue.
Investment score: 18/100
Analysis as of
Is BioRestorative Therapies Inc stock worth reviewing? AI model thesis
BRTX is a distressed micro-cap biotech on the verge of a liquidity crisis. Despite a high-quality patent pool, the math of a $1.5M cash pile against a $10M+ annual burn suggests a massive dilutive event or bankruptcy is the most likely outcome before its 2029 profitability targets can be reached.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 25/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
BioRestorative Therapies Inc opportunities and risks
What speaks for BRTX
- 2029 Profitability Projection
What speaks against BRTX
- Near-Term Liquidity Crunch
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BRTX | n/a | 4.6x | 0.1x | 92.1% | -3089.6% | -720.6% |
| AQB | n/a | 0.0x | n/a | 0.0% | 0.0% | -79445.0% |
| LUDG | n/a | 0.0x | n/a | 0.0% | 0.0% | -12.8% |
| MBIO | n/a | 0.0x | 3.7x | 0.0% | 0.0% | -100.4% |
| DRMA | n/a | 0.0x | 0.8x | 0.0% | 0.0% | -1032.4% |
| EGRX | 0.1x | 0.0x | 0.2x | 70.0% | 11.3% | 641.3% |
| Peer median | n/a | 0.0x | 0.2x | 0.0% | 0.0% | -100.4% |
Frequently asked questions about BioRestorative Therapies Inc (BRTX)
Is BRTX stock a good investment?
The cached TradeMates AI model rates BioRestorative Therapies Inc as AVOID with an investment score of 18/100. BRTX is a distressed micro-cap biotech on the verge of a liquidity crisis. Despite a high-quality patent pool, the math of a $1.5M cash pile against a $10M+ annual burn suggests a massive dilutive event or bankruptcy is the most likely outcome before its 2029 profitability targets can be reached. This is algorithmic model output, not personal investment advice.
Is BRTX stock a buy?
The TradeMates model verdict for BRTX is AVOID with an investment score of 18/100. Treat this as a model signal to review, not a personal buy recommendation.